Product logins

Find logins to all Clarivate products below.


Alison Isherwood

Director, Epidemiology & Real-World Evidence

Dr. Alison Isherwood is a Director in Clarivate’s Commercial Strategy Consulting Epidemiology & Real-World Evidence team.

Alison has over 16 years of consultancy experience in healthcare and life sciences consultancy, specializing in epidemiological and RWE-based insights and solutions. Her role is to use secondary data and US and European real-world data (RWD) to provide strategic epidemiological insights for business stakeholders in commercial and HEOR roles.

Alison held the roles of Research Scientist at Evidera designing and executing RWE-based outcomes research studies. Prior to this, she the Director of Epidemiology for DRG’s Syndicated Epidemiology team where she gained considerable experience in patient population sizing with incidence and prevalence risk-based forecast modelling across a portfolio of 200 diseases in over 40 countries.

She holds a Doctoral degree from the University of Reading (UK), and an MSc in Epidemiology, an MRes in Life Sciences and a BSc in Medical Microbiology all from the University of Edinburgh.


arrow_forward
Get in touch with Alison

Related resources

为何长寿研究可能成为生物制药的下一个风口:当科学与商业的交汇 为何长寿研究可能成为生物制药的下一个风口:当科学与商业的交汇
Blog March 2, 2026
为何长寿研究可能成为生物制药的下一个风口:当科学与商业的交汇
AI/机器学习 GLP-1 临床试验 交易 药政法规 衰老生物学
为何更方便的给药方式并未获得支付方青睐 为何更方便的给药方式并未获得支付方青睐
Blog February 26, 2026
为何更方便的给药方式并未获得支付方青睐
医疗保险 定价 市场准入 真实世界数据 美国市场
应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径 应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
Blog February 24, 2026
应对完整回复函:科睿唯安解决方案如何帮助制药公司规划其获批路径
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规
前进之路:收到 CRL 后该何去何从? 前进之路:收到 CRL 后该何去何从?
Blog February 24, 2026
前进之路:收到 CRL 后该何去何从?
FDA 临床试验 市场准入 最值得关注的药物 美国市场 药政法规